Literature DB >> 114069

Craniocervical chordomas.

R D Harwick, A S Miller.   

Abstract

In a 20 year period seven cases of craniocervical chordoma were seen and treated. Since it is not possible to completely resect these lesions, the aim of treatment has been to debulk the tumor as much as feasible and employ postoperative irridation. Palliation is the most that can be hoped for, and minimal success in delaying the natural history of the tumor has been achieved. Surgery for relief of symptoms secondary to bulky recurrence is indicated for palliation, as is a repeat course of x-ray therapy. Isolated cases of long-term useful survival have followed doses in the range of 10,000 rads or more [19,20]. This therapy is usually given in smaller increments of an initial dose when there is evidence of recurrent tumor or pain [2]. However, whenever the dosage to the spinal cord or the base of the brain exceeds 4,000 rads, there is a concern about possible permanent radiation damage. These patients are difficult to care for late in the course of their disease when multiple cranial nerve paralysis, long tract signs, and intractable pain become progressively severe. Chordomas usually remain localized; however, about 10% metastasize distally. One case is presented of a large retropharyngeal mass with destruction of the second cervical vertebra that recurred locally in 3 months despite usual treatment; distal bony metastases were found 3 years after initial treatment. The histology of the lesion, its recurrence, and distal bony metastases were essentially indistinguishable from the other lesions that remained localized. Short periods of palliation from severe local pain and exquisite tenderness have been achieved by local resection of the involved bones.

Entities:  

Mesh:

Year:  1979        PMID: 114069     DOI: 10.1016/0002-9610(79)90410-0

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  5 in total

1.  Chondroid chordoma of the base of the skull: orbital and other neuro-ophthalmological symptoms.

Authors:  L A Bastiaensen; A C Leyten; T G Tjan; J F Misere
Journal:  Doc Ophthalmol       Date:  1983-02-28       Impact factor: 2.379

2.  Chordomas with malignant spindle cell components. A DNA flow cytometric and immunohistochemical study with histogenetic implications.

Authors:  R H Hruban; F Traganos; V E Reuter; A G Huvos
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

Review 3.  Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma.

Authors:  Brian J Jian; Orin G Bloch; Isaac Yang; Seunggu J Han; Derick Aranda; Tarik Tihan; Andrew T Parsa
Journal:  J Neurooncol       Date:  2009-12-02       Impact factor: 4.130

Review 4.  Chemotherapy for cranial base tumors.

Authors:  H E Jacob
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Does chondroid chordoma exist?

Authors:  J J Brooks; V A LiVolsi; J Q Trojanowski
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.